Translational trends and specific nutritional interventions for aromatase inhibitor induced bone loss based on a 25 year multi database bibliometric and thematic evolution analysis from 2000 to 2025
- 1epartment of Breast and Thyroid Surgery, The First People's Hospital of Yunnan Province, Kunming, China
Abstract
BackgroundAccelerated bone loss is often observed in postmenopausal women with breast cancer receiving long-term aromatase inhibitor (AI) therapy; particularly, there is a growing need for targeted nutritional interventions.MethodsThis multi-database bibliometric study evaluated 25 years of literature from 2000 to 2025 retrieved from the Web of Science Core Collection and Scopus. Following PRISMA guidelines, 768 publications were assessed using R-based analytical workflows to examine output trends, collaboration networks, thematic evolution, and citation impact.ResultsAnnual scientific production expanded between 2005 and reached a peak in 2011, followed by a stable plateau of annual output through 2025. With strong institutional networks in North America and Europe, the United States was the productivity leader. A conceptual transition from isolated antiresorptive medications (bisphosphonates, denosumab) to an integrative bone microenvironment preservation strategy was suggested by keyword and thematic analyses. Keyword patterns suggested that Vitamin D and calcium are frequently integrated as universal baseline co-therapies, and topics including obesity, treatment-associated arthralgia, and survivorship exhibited high citation impact.ConclusionStudies on AI-associated bone loss (AIBL) have moved beyond routine BMD measurement to the structured co-management of micronutrients and metabolism, which may in turn guide future breast cancer survivorship research.
Related
- Omega-3 fatty acids in aromatase inhibitor-associated dyslipidemia: mechanisms, clinical evidence, and future perspectives
- Societal and Healthcare Costs of Post-IDFS Events Following Adjuvant Ribociclib Plus an Aromatase Inhibitor (AI) Versus AI Alone in Pre- and Postmenopausal Women with Early HR+/HER2- Breast Cancer in Canada.
- Baseline SII and SIRI identify immune-inflammatory susceptibility and improve risk stratification of early subclinical cardiac dysfunction during non-steroidal aromatase inhibitor therapy
- Safety and treatment duration of ribociclib + nonsteroidal aromatase inhibitor in HR+/HER2- early breast cancer: a phase 3 randomized controlled trial (NATALEE).
- Nutritional Interventions for Patients with Intermittent Claudication: Mechanisms, Clinical Implications, and the Case for Exercise-Adjunct Strategies: A Narrative Review
BibTeX
@article{huang2026translational,
title = {{Translational trends and specific nutritional interventions for aromatase inhibitor induced bone loss based on a 25 year multi database bibliometric and thematic evolution analysis from 2000 to 2025}},
author = {Zhenfan Huang and Yuyu Zhang and Qiongyu Wu and Shaoda Meng},
journal = {Frontiers in Nutrition},
year = {2026},
month = oct,
doi = {10.3389/fnut.2026.1969024},
url = {https://doi.org/10.3389/fnut.2026.1969024},
note = {CC BY},
}
RIS
TY - JOUR
TI - Translational trends and specific nutritional interventions for aromatase inhibitor induced bone loss based on a 25 year multi database bibliometric and thematic evolution analysis from 2000 to 2025
AU - Zhenfan Huang
AU - Yuyu Zhang
AU - Qiongyu Wu
AU - Shaoda Meng
PY - 2026
DA - 2026/10/26
JO - Frontiers in Nutrition
DO - 10.3389/fnut.2026.1969024
UR - https://doi.org/10.3389/fnut.2026.1969024
AB - BackgroundAccelerated bone loss is often observed in postmenopausal women with breast cancer receiving long-term aromatase inhibitor (AI) therapy; particularly, there is a growing need for targeted nutritional interventions.MethodsThis multi-database bibliometric study evaluated 25 years of literature from 2000 to 2025 retrieved from the Web of Science Core Collection and Scopus. Following PRISMA guidelines, 768 publications were assessed using R-based analytical workflows to examine output trends, collaboration networks, thematic evolution, and citation impact.ResultsAnnual scientific production expanded between 2005 and reached a peak in 2011, followed by a stable plateau of annual output through 2025. With strong institutional networks in North America and Europe, the United States was the productivity leader. A conceptual transition from isolated antiresorptive medications (bisphosphonates, denosumab) to an integrative bone microenvironment preservation strategy was suggested by keyword and thematic analyses. Keyword patterns suggested that Vitamin D and calcium are frequently integrated as universal baseline co-therapies, and topics including obesity, treatment-associated arthralgia, and survivorship exhibited high citation impact.ConclusionStudies on AI-associated bone loss (AIBL) have moved beyond routine BMD measurement to the structured co-management of micronutrients and metabolism, which may in turn guide future breast cancer survivorship research.
SN - 2296-861X
ER -